Boston Scientific has entered into a definitive agreement to acquire Axonics for $3.670 billion, with the transaction expected to close in the second half of 2024, pending regulatory approvals.

Emerging markets net sales grew by 22.6%, including operational net sales growth of 28.2%, driven by strong performance in China. This growth was partially offset by a negative impact of 550 basis points from foreign currency fluctuations.

The company's growth strategy is focused on product innovation, strong commercial execution, and expansion in emerging markets, as evidenced by the growth in various business segments and the acquisition of Axonics.

The company reported strong operational net sales growth across multiple business segments, including Endoscopy (12.1%), Urology (9.8%), and Cardiology (17.9%), indicating effective management execution.

The company acknowledges ongoing challenges from supply chain disruptions and inflation, which are impacting costs and product availability, indicating the need for continued management attention.

Management is actively pursuing global expansion, particularly in emerging markets, and strategic acquisitions, such as Axonics, to drive future growth and market share.

The company identifies geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, and trade restrictions, as risks that could impact its ability to operate and transfer capital.

The company acknowledges ongoing risks from cybersecurity events and supply chain disruptions, which could affect its business operations, data integrity, and product availability.

The company highlights risks associated with regulatory changes, litigation, and governmental investigations, which could impact product approvals, reimbursement, and financial results.

The company continues to expand its market presence in key segments such as LAAC procedures with WATCHMAN FLXTM and electrophysiology, despite competitive pressures.

The company continues to invest in R&D to develop new products and technologies to maintain its competitive edge and market position.

The company is expanding its global presence, particularly in emerging markets, to increase market share and drive future growth.

The company's 2023 restructuring plan is intended to simplify its manufacturing and distribution network, transfer production lines, and drive operational efficiencies and resiliency.

The company is actively working to address supply chain disruptions and cost increases through various optimization efforts.

The company is focused on managing costs and improving operational efficiency to mitigate the impact of inflation and other economic challenges.

The company continues to increase its investment in R&D to develop new medical technologies and products across its various business segments.

The company is focused on developing less-invasive medical technologies and products to improve patient outcomes and reduce healthcare costs.

The company is actively launching new products, including the Farapulse™ Pulsed Field Ablation System, to drive future sales growth.

The company issued €2.000 billion in euro-denominated senior notes to fund the repayment of existing debt and a portion of the Axonics acquisition.

The company did not repurchase any shares of its common stock during the first quarter of 2024, with the full $1.000 billion authorization still available.

The company continues to pursue strategic acquisitions, such as the pending acquisition of Axonics, to expand its market presence and product portfolio.

The company emphasizes its commitment to sustainable environmental, social, and governance practices, aligned with the United Nations Sustainable Development Goals.

The company's annual bonus plan includes performance measures for certain ESG goals, demonstrating a commitment to sustainability.

The company's global ESG vision and strategy is led by the ESG Executive Steering Committee, demonstrating a commitment to sustainability at the highest level.

The company acknowledges the ongoing impact of global supply chain disruptions and inflation, which are affecting costs and product availability.

The company identifies geopolitical risks, including the Russia/Ukraine war, Israel/Hamas war, and tensions in the Taiwan strait, as factors that could impact its business operations.

The company acknowledges the potential impact of healthcare policy changes and regulatory efforts, including changes to product approval and reimbursement processes.